SUMMARY Serum carcinoembryonic antigen concentrations (serum CEA) in 80 patients with primary breast cancer were measured preoperatively, one month after operation, and thereafter serially every third month. These data were related to histological and morphometric features of the primary breast carcinoma and the lymph node metastases and to clinical follow up data.
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organs affected by metastases, date of appearance of distant metastases, type of treatment, and cause of death. All patients studied were examined every three months postoperatively during the first two years and every six months thereafter. At each control visit measurement of serum CEA formed part of the routine haematological, biochemical, and physical examinations. X ray films of the thorax were obtained every six months, in addition to those made because of symptoms verbalised by the patient or physical findings, or both. Distant metastasis was diagnosed if a combination of clinical, radiographic, scintigraphic, and biochemical data (excluding CEA values) were conclusive, or if metastasis was diagnosed histologically. Both local and distant metastases were considered. Patients with local recurrence (in the skin, axilla, and mastectomy scar) and one patient with contralateral breast disease were separately considered in the study; histological examination did not determine whether this last patient had a second primary tumour or a metastasis. HISTOLOGICAL 
METHODS
The size of the primary tumour was assessed on the excision specimen. The primary breast tumours and all the available lymph nodes were fixed in 5% buffered formalin and subsequently embedded in paraplast. From this material tissue sections 4 ,um thick were stained with haematoxylin and eosin. The condition of the lymph nodes and the following histological features of the primary carcinoma were assessed.
HISTOLOGICAL TUMOUR TYPE
All 80 cases of breast carcinoma were classified according to the World Health Organisation recommendations'8: ductal (n = 68); lobular (n = 1); medullary (n = 4); and others (n = 7). Nuclear grading was performed according to Black et Tables 1 and 2 show the data from serum CEA concentrations (those measured preoperatively and one month after operation, and the highest values) and Table 2 ). Analysis by linear regression of the data on oestrogen receptor and serum CEA concentrations showed that a significant correlation between these features was present for only the period one month to 18 months after operation (data not shown). Analysis of the clinical data showed a clear correlation between an increase in serum CEA concentrations and the recurrence of the disease (locally or with distant metastases, or both) (Wilcoxon: p < 0-001, Fig. 1 ). During the follow up period recurrences were diagnosed clinically in 19 patients (24%) (three patients had local recurrence). Fifteen of these (79%) had serum CEA values >5 ng/ml (Fig. 1) .
Analysis of the 15 patients with serum CEA concentrations >5 ng/ml showed that seven had shown an increase in concentration more than one month before the clinical diagnosis of the recurrence. In four patients it was not completely clear from the clinical data whether the increase in concentration had preceded or succeeded the clinical diagnosis. In four other patients the increase occurred more than one month after the clinical diagnosis of the recurrence (Fig. 2) Table 3 shows the data on these combinations. In the analysis (x2) highest CEA values of more than 5 ng/ml (CEA-H +) were compared with those 5 -ng/ml (CEA-H -). The combination of (-v +) when related to highest CEA value and presence or absence of lymph node metastases was significant (X2 = 28-8 v = 3, p < 0 001, Table 3 ). Ten of 14 patients (71 %) who were CEA-H positive and lymph node positive developed distant metastases whereas none of the 26 patients who were CEA-H negative/lymph node negative did. Thus CEA-H positive/lymph node positive patients had significantly more recurrences than those who were negative. The combination of CEA-H and size of tumour was significant (X2 = 26-0, v = 3, p < 0 001; Table 3 ) when related to tumour recurrence. None of the 26 CEA-H negative patients with a tumour <2 cm had recurrence. Eleven out of 19 (58%) of the CEA-H positive group with a tumour -2 cm developed recurrent disease. Table 3 shows the significant correlation between the development of recurrences and the combination of CEA-H level and oestrogen receptor state (X2 = 15-3, v = 2, p < 0-001). Although this correlation when compared with the above correlations was not that significant, it was an interesting factor, for six patients of 12 who were CEA-H positive/ oestrogen receptor positive had tumour recurrence.
Discussion
A significant correlation was found between the highest serum CEA concentrations and recurrence of the disease (Fig. 1) . This correlation has also been van der Linden., Baak, Posima, Lindeman, Meyer
Monitoring serum CEA in women with primary breast tumours found in other studies.369 12 13 In our study 15 of 19 (79%) patients with serum CEA values >5 ng/ml developed recurrences. This percentage is somewhat higher than that described in published reports (range 30-71%). This is obviously because most of the studies took 10 ng/ml as the cut off point. If this threshold had been adopted in the present study the sensitivity would have fallen to 57% (11/19), which is more in line with other studies. With 5 ng/ml as a threshold 23 patients had concentrations above that value more than two months after the operation and 13 had concentrations above 10 ng/ml. Therefore, 13 patients had values between 5 and 10 ng/ml. Of these, four developed distant metastasis (and no local recurrence). This high percentage clearly supports the choice of 5 instead of 10 ng/ml as the threshold.
Of the four patients with metastases and without a serum CEA value >5 ng/ml, three had local recurrence. This is in agreement with the findings of Haagensen et al7 and Lee.9 Apparently, local metastases can be easily missed when monitoring serum CEA for recurrence, but physical examination should easily detect these recurrences. Eight patients had increased serum CEA concentrations without confirmed metastatic disease (Table  1) . Two of these had values above 10 ng/ml. One patient developed carcinoma in the contralateral breast. This was not regarded as a metastasis, although the tumour was detected by an increase in serum CEA. The other patient had a large (>6 cm) breast carcinoma (without lymph node metastases) at presentation. The high serum CEA value decreased and became normal within two months after the operation, and no distant metastases were found during the follow up period. In four of the patients with serum CEA values >5 ng/ml but 610 ng/ml the values also decreased below 2 5 ng/ml in the first three postoperative months.
This finding may have been due to the fact that it takes time for CEA to be degraded.'5 Our results support the theory that estimations of serum CEA should be started two or three months after operation to remove primary breast carcinoma and that 5 ng/ml is a reasonable threshold value. In this study only two of 65 patients (31%) gave false positive results. This is lower than the value found by Lee, who found falsely increased serum CEA concentrations in his patients. 9 Meyers et al found a correlation between serum CEA values established within three months after operation and the presence of lymph node metastases." In that study a quarter of the patients with spread to lymph nodes were also positive for serum CEA compared with 13-9% of the patients without such spread. Values >4 ng/ml were regarded as positive. In our study this difference was also found between patients with positive lymph nodes and those with negative lymph nodes, and the preoperative serum CEA values (19.5% compared with 3-4%; Table 2 ). In addition, Meyers (Table  2 ). This is in keeping with the belief that patients with larger primary tumours and spread to lymph nodes are more likely to develop metastases.
In this study not one patient with an oestrogen receptor negative tumour had a serum CEA value >5 ng/ml. This is strange because oestrogen receptor negative tumours tend to have a worse prognosis. Although the number of patients was small (n = 51) and further investigation is required, Table 3 shows that all the patients with a recurrence were either oestrogen receptor negative and CEA negative or oestrogen receptor positive and CEA positive. By monitoring serum CEA in patients positive for oestrogen receptor recurrence can be detected in this group of patients with an apparently better prognosis.
Our results show that the appearance of distant metastases in patients with primary breast cancer can be monitored in the first two years after operation by serial estimations of serum CEA only in patients with tumours >2 cm that are positive for oestrogen receptor who have spread to the lymph nodes.
Supported in part by grant 28-735 from Praeventiefonds.
